首页|期刊导航|中国中药杂志|基于Meta分析整合网络药理学和实验验证研究策略探讨盘龙七片治疗骨折的作用特点和机制

基于Meta分析整合网络药理学和实验验证研究策略探讨盘龙七片治疗骨折的作用特点和机制OA

Action characteristics and mechanisms of Panlongqi Tablets in treating fractures based on research strategy integrating Meta-analysis,network pharmacology,and experimental verification

中文摘要英文摘要

该研究采用 Meta 分析结合网络药理学与实验验证的研究策略和方法,旨在明确盘龙七片治疗骨折的临床效果和作用特点,并初步揭示相关作用机制.首先,检索并纳入符合标准的盘龙七片治疗骨折随机对照试验(RCTs)13 项,分析结果显示,与对照组相比,盘龙七片能明显改善患者影像学表现与运动功能,提高总有效率,尚能降低肿胀积分和凝血指标,升高骨生成因子,促进骨折愈合.收集 GEO 数据库中大鼠骨折不同阶段(骨折 7、14、28 d)差异基因集(GSE262132),利用 TCMSP 等数据库获取盘龙七片的药物靶标谱.通过使用 Jaccard 与余弦相似度进行"疾病不同时期-方药"对应性评价,发现对应性最佳为7 d(早期);通过构建"骨折不同时期差异基因-盘龙七片候选靶标"网络进行功能富集分析,发现各期的核心靶标均富集于调控炎症免疫、疼痛、血液循环和骨代谢的信号通路,其中相关性最强的为磷脂酰肌醇 3-激酶(PI3K)-蛋白激酶 B(Akt)信号通路.采用大鼠胫骨横断性骨折模型对上述候选信号分子进行机制验证,其中 Western blot 检测 PI3K、Akt、磷酸化蛋白激酶 B(p-Akt)和血管内皮生长因子 A(VEGFA)的表达水平,ELISA 检测转化生长因子-β(TGF-β)、骨形态发生蛋白-2(BMP-2)、骨源性碱性磷酸酶(BALP)、Ⅰ型前胶原氨基端前肽(PINP)和骨钙素(OCN)的表达水平,结果显示,盘龙七片能显著提高愈伤组织中PI3K、p-Akt、Akt 和 VEGFA 的蛋白表达水平,也能明显升高血清中 TGF-β、BMP-2、BALP、PINP、OCN 的含量,表明盘龙七片促进骨折愈合的机制可能与激活 PI3K-Akt 信号通路有关.研究结果有助于阐明盘龙七片的功效内涵,指导盘龙七片临床合理用药.

This study adopted a research strategy and method integrating Meta-analysis,network pharmacology,and experimental verification,aiming to clarify the clinical effect and action characteristics of Panlongqi Tablets in treating fractures and preliminarily re-veal the related action mechanism.Firstly,13 randomized controlled trials(RCTs)of Panlongqi Tablets for treating fractures that met the criteria were retrieved and included.The analysis results show that compared with the control group,Panlongqi Tablets could signi-ficantly improve the imaging manifestations and motor function of patients,increase the total effective rate,reduce the swelling score and coagulation indicators,and increase the osteogenic factors,thereby promoting fracture healing.Secondly,the differential gene set of rat fractures at different stages(seven,14,and 28 days)in the GEO database,namely GSE262132,was collected,and the drug target spectra of Panlongqi Tablets were obtained from databases such as TCMSP.Through the correspondence evaluation for the"disease at different stages and prescription"by using Jaccard and cosine similarity,it was found that the best correspondence was at seven days(early stage).Through the construction of the"differential genes at different fracture stages and candidate targets of Pan-longqi Tablets"interaction network for functional enrichment analysis,it was found that the core targets in each stage were enriched in signaling pathways regulating inflammation immunity,pain,blood circulation,and bone metabolism,among which the correlation was the strongest as the phosphatidylinositol-3-kinase(PI3K)-protein kinase B(Akt)signaling pathway.The mechanism of the above can-didate signaling molecules was verified by using a rat model of tibial transverse fracture.Western blot was used to detect the expression levels of PI3K,Akt,phosphorylated protein kinase B(p-Akt),and vascular endothelial growth factor A(VEGFA),and ELISA was used to detect the expression levels of transforming growth factor β(TGF-β),bone morphogenetic protein-2(BMP-2),bone alkaline phosphatase(BALP),type I procollagen amino-terminal propeptide(PINP),and osteocalcin(OCN).The results show that Pan-longqi Tablets could significantly increase the protein expression levels of PI3K,p-Akt,Akt,and VEGFA in the healing tissue and could significantly elevate the contents of TGF-β,BMP-2,BALP,PINP,and OCN in the serum,indicating that the mechanism of Panlongqi Tablets promoting fracture healing may be related to the activation of the PI3K-Akt signaling pathway.The research results are helpful to clarify the efficacy connotation of the"Qi yao"and guide the rational clinical medication of Panlongqi Tablets.

李晓萱;林娜;王佳琳;李玮婕;刘毓东;严倩倩;赵清玉;张彦琼;林雅;刘春芳

道地药材品质保障与资源持续利用全国重点实验室,中国中医科学院 中药研究所,北京 100700||福建中医药大学 药学院,福建 福州 350122道地药材品质保障与资源持续利用全国重点实验室,中国中医科学院 中药研究所,北京 100700道地药材品质保障与资源持续利用全国重点实验室,中国中医科学院 中药研究所,北京 100700道地药材品质保障与资源持续利用全国重点实验室,中国中医科学院 中药研究所,北京 100700道地药材品质保障与资源持续利用全国重点实验室,中国中医科学院 中药研究所,北京 100700道地药材品质保障与资源持续利用全国重点实验室,中国中医科学院 中药研究所,北京 100700道地药材品质保障与资源持续利用全国重点实验室,中国中医科学院 中药研究所,北京 100700道地药材品质保障与资源持续利用全国重点实验室,中国中医科学院 中药研究所,北京 100700福建中医药大学 药学院,福建 福州 350122道地药材品质保障与资源持续利用全国重点实验室,中国中医科学院 中药研究所,北京 100700

盘龙七片骨折Meta分析网络药理学临床疗效

Panlongqi TabletsfractureMeta-analysisnetwork pharmacologyclinical efficacy

《中国中药杂志》 2026 (17)

4827-4837,11

中国中医科学院科技创新工程项目(CI2024E003KC-05)中国中医科学院中药研究所技术服务项目(H2024003)

10.19540/j.cnki.cjcmm.20260120.701

评论